The modulation of cellular processes by small molecule inhibitors, gene
inactivation, or targeted knockdown strategies combined with phenotypic
screens are powerful approaches to delineate complex cellular pathways and to
identify key players involved in disease pathogenesis. Using chemical genetic
screening, we tested a library of known phosphatase inhibitors and identified
several compounds that protected
Bacillus anthracis infected
macrophages from cell death. The most potent compound was assayed against a
panel of sixteen different phosphatases of which CD45 was found to be most
sensitive to inhibition. Testing of a known CD45 inhibitor and antisense
phosphorodiamidate morpholino oligomers targeting CD45 also protected
B.
anthracis-infected macrophages from cell death. However, reduced CD45
expression did not protect anthrax lethal toxin (LT) treated macrophages,
suggesting that the pathogen and independently added LT may signal through
distinct pathways. Subsequent,
in vivo studies with both
gene-targeted knockdown of CD45 and genetically engineered mice expressing
reduced levels of CD45 resulted in protection of mice after infection with the
virulent Ames
B. anthracis. Intermediate levels of CD45 expression
were critical for the protection, as mice expressing normal levels of CD45 or
disrupted CD45 phosphatase activity or no CD45 all succumbed to this pathogen.
Mechanism-based studies suggest that the protection provided by reduced CD45
levels results from regulated immune cell homeostasis that may diminish the
impact of apoptosis during the infection. To date, this is the first report
demonstrating that reduced levels of host phosphatase CD45 modulate anthrax
pathogenesis.Interactions between microbes and immune cells play a critical role in
microbial pathogenesis. Many pathogenic organisms exploit the host immune
machinery and subsequently modulate cell function, signaling, migration, and
cytoskeleton rearrangement. Hence, identifying host cellular components with
which microbes interact will allow for a more comprehensive understanding of
microbial pathogenesis, define common strategies used by multiple pathogens,
and elucidate unique tactics evolved by individual species to help establish
infections or evade host innate responses. Another interesting aspect of
infection is that diverse pathogens seem to target common cellular pathways
(
1,
2). Thus, identifying host
targets exploited by multiple pathogens will be useful in the development of
broad-spectrum host-oriented therapeutics and vaccines.Protein kinases and phosphatases regulate a range of cellular responses to
external and internal stimuli, including cell proliferation, metabolism, and
apoptosis. Aberrant kinase and/or phosphatase activities underlie many
different types of pathological conditions from cancer to infectious diseases.
Protein kinases have been extensively investigated as targets for drug
discovery. In addition, phosphatases are now being recognized as important
regulators of many biological processes. In particular, there is an increasing
interest in protein-tyrosine phosphatases
(PTPs)
3 as drug
targets
(
3–
8)
because immune cells express a remarkably high proportion of the 107 PTP genes
in the human genome (
9) and
also due to the growing number of human diseases discovered to be associated
with PTP abnormalities
(
9–
11).
The involvement of cellular and bacterial PTPs during intracellular microbial
pathogenesis has been a topic of significant interest
(
2,
12,
13). The bacterial PTP YopH,
secreted by
Yersinia pestis, interferes with the host
adhesion-regulated signaling pathway via dephosphorylation of selective
tyrosine-phosphorylated proteins
(
14). Activation of host PTPs
after infection with bacteria or their virulence factors has been demonstrated
for a diverse group of microorganisms such as
Mycobacterium
tuberculosis and
Leishmania donovani
(
13). Specific mechanistic
models of how PTPs contribute to the development of infection and disease
progression by highly lethal organisms still remain unclear.
Bacillus anthracis, a Gram-positive spore-forming bacterium, is
the etiologic agent of anthrax. The lethal toxin (LT) produced by
B.
anthracis can cleave host cell mitogen-activated protein kinase kinases
(MAPKK), thereby affecting the immune response and the host ability to fight
the infection (
15,
16). Macrophages are the
primary targets of anthrax LT. However, macrophages from only certain strains
of mice are susceptible to LT-mediated cell death
(
17,
18). To date, there is no
known direct relation between MAPKK cleavage and LT-induced macrophage cell
death, as LT-resistant macrophages exhibit MAPKK cleavage
(
19–
21).
This suggests that another cellular target(s) may play a role in anthrax
pathogenesis.Previously, using a chemical genetic approach, we identified a class of
Cdc25 inhibitors that protected macrophages from cell death induced by anthrax
LT (
22). Although Cdc25 was
not the cellular target, induction of anti-apoptotic responses by the
compounds via either the MAPK-dependent or -independent pathways was
responsible for the protective phenotype.In the present study we investigated if the previously identified
phosphatase inhibitors (
22)
and their analogs produced any phenotypic changes in the
B. anthracis
infection model. Two compounds that previously protected LT-treated
macrophages (
22) also protect
B. anthracis-infected macrophages. Subsequent
in vitro
phosphatase profiling studies identified CD45, a previously unknown target of
one of the small molecules, as the most sensitive enzyme to the inhibitor. We
then investigated the effect of CD45 reduction in anthrax pathogenesis both in
cells and
in vivo by using antisense phosphorodiamidate morpholino
oligomers and mice engineered to express reduced levels of CD45.
相似文献